info@athenex.com716.427.2950
AthenexAthenex
Athenex
Improving the lives of cancer patients everywhere
  • About
    • About Athenex
    • Our Other Companies
    • Our Partnerships
  • Oncology Innovation
    • Orascovery Platform
    • Src Kinase Inhibition
    • Dual Inhibition
    • Clinical Trials
  • Operating Platforms
    • Commercial Segment
    • Internal Supply Chain
  • Our Team
    • Our Board of Directors
    • Our Leadership Team
    • Other Key Employees
    • Our Advisors
  • Careers
  • Investor Relations
    • Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Investor Calendar
      • Presentations
    • Financial Information
      • SEC Filings
      • Annual Meeting Materials
      • Annual Reports
      • Quarterly Results
    • Corporate Governance
      • Governance Highlights
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Information Request
      • E-mail Alerts
      • IR Contacts
Menuback 
 

Press Releases

« Back
Printer Friendly Version View printer-friendly version
February 26, 2018Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018

BUFFALO, N.Y., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release fourth quarter and full year 2017 earnings results on March 26, 2018. The Company will host a conference call and audio webcast on Monday, March 26, 2018 at 9:00 a.m. Eastern Time.

To participate in the call, dial (855) 227-0567 (domestic) or (612) 979-9912 (international) fifteen minutes before the conference call begins and reference the conference passcode 4156727. A replay will be available approximately one hour after the recording through Monday, April 2, 2018 and can be accessed by dialing (855) 859-2056. The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at www.athenex.com.  An archive will be available at this website until April 26, 2018.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.

CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.

Athenex, Inc.
  • Print Page Print Page
  • E-mail Page E-mail Page
  • RSS RSS
  • E-mail Alerts E-mail Alerts
  • Tearsheet Tearsheet
Athenex - Improving the lives of cancer patients everywhere
Learn More
Our Company

Athenex is an innovative oncology company with drug discovery, drug formulation, clinical development, and API/drug product manufacturing facilities in both the U.S. and China. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments.

Other Athenex Companies

Polymed Therapeutics
Athenex Pharma Solutions
CDE

Learn More

Contact Us

North American Headquarters


Conventus Building
1001 Main Street
Suite 600
Buffalo, New York 14203

P: (1) 716.427.2950
F: (1) 716.800.6816
E: info@athenex.com

Asia Headquarters


Unit 608-613, IC Development Centre,
No. 6 Science Park West Avenue,
Hong Kong Science Park, Sha Tin, New Territories, Hong Kong

P: (852) 2607.4100
F: (852) 3996.7454

Other Athenex Addresses

Athenex Pharmaceutical Division
10 N. Martingale Road, Suite 230
Schaumburg, IL 60173

Athenex New Jersey
20 Commerce Drive, Suite 100
Cranford, NJ 07016

Polymed Therapeutics
3040 Post Oak Blvd., Suite 110
Houston, TX 77056

Chongqing Taihao Pharmaceutical
C-5 #105 C-5, Er Lang Chuang Ye Road,
Jiulongpo District, Chongqing, China

News & Press
  • Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
    February 14, 2019
  • Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
    February 04, 2019
  • Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
    January 09, 2019

© Athenex, Inc. All rights reserved

  • Home
  • About Us
  • Oncology Innovation
  • Operating Platforms
  • Our Team
  • Careers
  • Investor Relations
  • Contact Us
Footer Menu